Patents by Inventor Michael F. T. Koehler
Michael F. T. Koehler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240116872Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.Type: ApplicationFiled: October 18, 2023Publication date: April 11, 2024Applicants: GENENTECH, INC., CURIS, INCInventors: Janet L. GUNZNER-TOSTE, Daniel SUTHERLIN, Mark S. STANLEY, Liang BAO, Georgette M. CASTANEDO, Rebecca L. LALONDE, Shumei WANG, Mark E. REYNOLDS, Scott J. SAVAGE, Kimberly MALESKY, Michael S. DINA, Michael F.T. KOEHLER
-
Publication number: 20230265054Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.Type: ApplicationFiled: March 10, 2023Publication date: August 24, 2023Applicants: GENENTECH, INC., CURIS, INC.Inventors: Janet L. GUNZNER-TOSTE, Daniel P. SUTHERLIN, Mark S. STANLEY, Liang BAO, Georgette M. CASTANEDO, Rebecca L. LALONDE, Shumei WANG, Mark E. REYNOLDS, Scott J. SAVAGE, Kimberly MALESKY, Michael S. DINA, Michael F.T. KOEHLER
-
Publication number: 20230133817Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: ApplicationFiled: December 8, 2022Publication date: May 4, 2023Inventors: Yongsheng Chen, Peter Andrew Smith, Tuker Curran Roberts, Robert I. Higuchi, Prasuna Paraselli, Michael F.T Koehler, Jacob Bradley Schwarz, James John Crawford, Cuong Q. Ly, Emily J. Hanan, Huiyong Hu, Zhiyong Yu
-
Publication number: 20230133667Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: ApplicationFiled: October 18, 2022Publication date: May 4, 2023Inventors: Peter Andrew Smith, Tucker Curran Roberts, Robert I. Higuchi, Prasuna Paraselli, Michael F. T. Koehler, Jacob Bradley Schwarz, James John Crawford, Cuong Q. Ly, Emily J. Hanan, Huiyong Hu, Yongsheng Chen, Zhiyong Yu, Paul Colin Michael Winship, Calum MacCleod, Toby Blench
-
Publication number: 20220135528Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidases SpsB and/or LepB, an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: ApplicationFiled: December 17, 2021Publication date: May 5, 2022Inventors: Michael F.T. Koehler, Peter Andrew Smith, Dana Winter, Boubacar Sow, Claudio Sturino, Guillaume Pelletier, Jonathan Boudreault
-
Patent number: 11208387Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidases SpsB and/or LepB, an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: GrantFiled: May 27, 2020Date of Patent: December 28, 2021Assignee: Genentech, Inc.Inventors: Michael F. T. Koehler, Peter Andrew Smith, Dana Winter, Boubacar Sow, Claudio Sturino, Guillaume Pelletier, Jonathan Boudreault
-
Patent number: 11072635Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: GrantFiled: November 21, 2016Date of Patent: July 27, 2021Assignees: RQX Pharmaceuticals, Inc., Genentech, Inc.Inventors: Yongsheng Chen, Peter Andrew Smith, Tucker Curran Roberts, Robert I. Higuchi, Prasuna Paraselli, Michael F. T. Koehler, Jacob Bradley Schwarz, James John Crawford, Cuong Q. Ly, Huiyong Hu, Zhiyong Yu
-
Publication number: 20210198316Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: ApplicationFiled: August 13, 2019Publication date: July 1, 2021Inventors: Peter Andrew SMITH, Tucker Curran ROBERTS, Robert I. HIGUCHI, Prasuna PARASELLI, Michael F. T. KOEHLER, Jacob Bradley SCHWARZ, James John CRAWFORD, Cuong Q. LY, Emily J. HANAN, Huiyong HU, Yongsheng CHEN, Zhiyong YU, Paul Colin Michael WINSHIP, Calum McCleod, Toby Blench
-
Publication number: 20210070707Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.Type: ApplicationFiled: October 27, 2020Publication date: March 11, 2021Applicants: GENENTECH, INC., CURIS, INC.Inventors: Janet L. GUNZNER-TOSTE, Daniel SUTHERLIN, Mark S. STANLEY, Liang BAO, Georgette M. CASTANEDO, Rebecca L. LALONDE, Shumei WANG, Mark E. REYNOLDS, Scott J. SAVAGE, Kimberly MALESKY, Michael S. DINA, Michael F.T. KOEHLER
-
Publication number: 20200377463Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidases SpsB and/or LepB, an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: ApplicationFiled: May 27, 2020Publication date: December 3, 2020Inventors: Michael F.T. Koehler, Peter Andrew Smith, Dana Winter, Boubacar Sow, Claudio Sturino, Guillaume Pelletier, Jonathan Boudreault
-
Publication number: 20200239519Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: ApplicationFiled: November 21, 2016Publication date: July 30, 2020Inventors: Yongsheng CHEN, Peter Andrew SMITH, Tucker Curran ROBERTS, Robert I. HIGUCHI, Prasuna PARASELLI, Michael F. T. KOEHLER, Jacob Bradley SCHWARZ, James John CRAWFORD, Cuong Q. LY, Huiyong HU, Zhiyong YU
-
Publication number: 20200190030Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.Type: ApplicationFiled: February 21, 2020Publication date: June 18, 2020Applicants: GENENTECH, INC., CURIS, INC.Inventors: Janet L. GUNZNER-TOSTE, Daniel P. SUTHERLIN, Mark S. STANLEY, Liang BAO, Georgette M. CASTANEDO, Rebecca L. LALONDE, Shumei WANG, Mark E. REYNOLDS, Scott J. SAVAGE, Kimberly MALESKY, Michael S. DINA, Michael F.T. KOEHLER
-
Publication number: 20200024309Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: ApplicationFiled: August 13, 2019Publication date: January 23, 2020Inventors: Peter Andrew SMITH, Tucker Curran ROBERTS, Robert I. HIGUCHI, Prasuna PARASELLI, Michael F. T. KOEHLER, Jacob Bradley SCHWARZ, James John CRAWFORD, Cuong Q. LY, Emily J. HANAN, Huiyong HU, Yongsheng CHEN, Zhiyong YU, Paul Colin Michael WINSHIP, Calum McCleod, Toby Blench
-
Publication number: 20200010420Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.Type: ApplicationFiled: September 18, 2019Publication date: January 9, 2020Applicants: GENENTECH, INC., CURIS, INC.Inventors: Janet L. GUNZNER-TOSTE, Daniel SUTHERLIN, Mark S. STANLEY, Liang BAO, Georgette M. CASTANEDO, Rebecca L. LALONDE, Shumei WANG, Mark E. REYNOLDS, Scott J. SAVAGE, Kimberly MALESKY, Michael S. DINA, Michael F.T. KOEHLER
-
Patent number: 10392422Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: GrantFiled: May 19, 2015Date of Patent: August 27, 2019Assignees: RQX PHARMACEUTICALS, INC., GENENTECH, INC.Inventors: Tucker Curran Roberts, Peter Andrew Smith, Robert I. Higuchi, Prasuna Paraselli, Philippe Bergeron, Michael F. T. Koehler, Huiyong Hu, Jacob Bradley Schwarz, Cuong Ly, James John Crawford
-
Patent number: 10351595Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: GrantFiled: May 19, 2015Date of Patent: July 16, 2019Assignees: RQX PHARMACEUTICALS, INC., GENENTECH, INC.Inventors: Tucker Curran Roberts, Peter Andrew Smith, Robert I. Higuchi, Prasuna Paraselli, Philippe Bergeron, Michael F. T. Koehler, Huiyong Hu, Jacob Bradley Schwarz, Cuong Ly, James John Crawford
-
Publication number: 20180327367Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: ApplicationFiled: November 21, 2016Publication date: November 15, 2018Inventors: Yongsheng CHEN, Peter Andrew SMITH, Tucker Curran ROBERTS, Robert I. HIGUCHI, Prasuna PARASELLI, Michael F. T. KOEHLER, Jacob Bradley SCHWARZ, James John CRAWFORD, Cuong Q. LY, Emily J. HANAN, Huiyong HU, Zhiyong YU
-
Publication number: 20180258043Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.Type: ApplicationFiled: March 7, 2018Publication date: September 13, 2018Applicants: GENENTECH, INC., CURIS, INC.Inventors: Janet L. GUNZNER-TOSTE, Daniel P. SUTHERLIN, Mark S. STANLEY, Liang BAO, Georgette M. CASTANEDO, Rebecca L. LALONDE, Shumei WANG, Mark E. REYNOLDS, Scott J. SAVAGE, Kimberly MALESKY, Michael S. DINA, Michael F.T. KOEHLER
-
Publication number: 20180029984Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.Type: ApplicationFiled: October 3, 2017Publication date: February 1, 2018Applicants: GENENTECH, INC., CURIS, INC.Inventors: Janet L. GUNZNER-TOSTE, Daniel SUTHERLIN, Mark S. STANLEY, Liang BAO, Georgette M. CASTANEDO, Rebecca L. LALONDE, Shumei WANG, Mark E. REYNOLDS, Scott J. SAVAGE, Kimberly MALESKY, Michael S. DINA, Michael F.T. KOEHLER
-
Patent number: 9790183Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.Type: GrantFiled: February 4, 2016Date of Patent: October 17, 2017Assignee: GENENTECH, INC.Inventors: Janet L. Gunzner-Toste, Daniel Sutherlin, Mark S. Stanley, Liang Bao, Georgette M. Castanedo, Rebecca L. Lalonde, Shumei Wang, Mark E. Reynolds, Scott J. Savage, Kimberly Malesky, Michael S. Dina, Michael F. T. Koehler
